Skip to main content
Fig. 5 | BMC Pulmonary Medicine

Fig. 5

From: Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Fig. 5

A Cox regression analysis of factors associated with progression-free survival in 85 non-small cell lung carcinoma (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations treated with immune checkpoint inhibitor (ICI) combinations. B Cox regression analysis of factors associated with overall survival in 85 NSCLC patients with EGFR mutations treated with ICI combinations

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us